MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor

Ruben A. Mesa, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali, David Lavie, Andrew Kuykendall, Sebastian Grosicki, Alessandra Iurlo, Yeow Tee Goh, Mihaela Lazaroiu, Miklós Egyed, María Laura Fox, Donal P. McLornan, Andrew C. Perkins, Sung‐Soo Yoon, Vikas Gupta, Jean‐Jacques Kiladjian, Rafe Donahue, Jun Kawashima, Srđan Verstovšek
In: Clinical Lymphoma Myeloma and Leukemia · 2022 · vol. 22 , pp. S339–S340 · doi:10.1016/s2152-2650(22)01463-x · W4296468442
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-14 ⓘ

The MOMENTUM trial randomized symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor to receive either momelotinib or danazol.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-05-10T11:12:16.133615+00:00
License: CC0 · commercial use OK